Sysmex and Thinkcyte Agree on Joint Development and Capital Alliance
Commencing development of novel AI-based cell analyzers and testing techniques
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and ThinkCyte, Inc. (HQ: Bunkyo-Ku, Tokyo, Japan; CEO: Waichiro Katsuda) announced the signing of joint development and investment agreements during May 2021 for the commercialization of an AI-based cell analysis technology.
As healthcare becomes more precise and personalized at an accelerated rate – in tandem with the advancement of technology, the development of novel testing and diagnostic technologies with high clinical value is being sought to increase the accuracy of diagnoses and optimize treatment. Meanwhile, digitalization is rapidly gaining pace in healthcare fields such as telehealth, AI-powered medical imaging analysis, and automated testing using robots.
Recommended AI News: UCM Digital Health Adds Healthcare and Technology Executive John Kelleher to Leadership Team
Sysmex has been proactively acquiring technologies for analyzing cells, genes, and proteins with a high degree of precision and sensitivity. Among those technologies, a cell analysis platform has been applied to a diverse range of Sysmex products. Sysmex’s current focus in this field is to develop technology that precisely analyzes cells using various kinds of information such as cell function and responsiveness, in addition to seeking greater speed in cell analysis.
ThinkCyte possesses “Ghost Cytometry technology,”[1] which analyzes morphological information of cells in a fast and simplified process, while the information that this technology gathers is far richer than what can be obtained by using the conventional flow cytometry (FCM) technique. Beyond counting and analyzing cells based on their simple morphological features, this technology allows users to classify each cell based on its detailed morphological information with respect to its characteristics and functions. This high-resolution analysis will enable highly effective determination of clinical conditions using bodily fluids such as blood, increase accuracy in a wide range of cell-based diagnoses, and lead to better-personalized healthcare.
Recommended AI News: Ellucian Announces Steve Harris as Chief Revenue Officer
As a result of ongoing collaborative research between Sysmex and ThinkCyte increasing the feasibility of applying Ghost Cytometry technology to diagnostic techniques with high clinical value, on March 31, 2021, the two companies signed a memorandum of understanding to start full-fledged joint development of the novel AI-based cell analysis technology. Furthermore, on May 1, 2021, the two companies agreed on joint development, pursuant to which efforts will be made to commercialize cell analyzers and testing techniques using Ghost Cytometry technology for cell analysis (including research purposes) in the field of in-vitro diagnostics (IVD). Meanwhile, Sysmex agreed on an equity investment in ThinkCyte on May 11, 2021, which is expected to allow the two companies to reinforce their robust partnership.
Through the alliance, Sysmex and ThinkCyte aim to develop novel cell analysis technology and testing techniques by integrating Sysmex’s wealth of knowledge and expertise in IVD and ThinkCyte’s proprietary Ghost Cytometry technology, thus contributing to the advancement and evolution of healthcare the world over.
Recommended AI News: Cryptosense Raises $4.8 Million to Accelerate Its Cryptography Lifecycle Management Software
Comments are closed.